SARISSA INC has a total of 19 patent applications. Its first patent ever was published in 1998. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are CYTOVAC AS, THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE and HAN HOON.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | United States | 5 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | Australia | 2 | |
#5 | Canada | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Enzymes | |
#5 | Sugars | |
#6 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Vincent Mark D | 14 |
#2 | Koropatnick D James | 10 |
#3 | Rytelewski Mateusz | 6 |
#4 | Ferguson Peter J | 4 |
#5 | Vincent Mark | 4 |
#6 | Ferguson Peter | 3 |
#7 | Koropatnick James D | 2 |
#8 | Berg Randall W | 1 |
#9 | Dean Nicholas Mark | 1 |
#10 | Dean Nicholas M | 1 |
Publication | Filing date | Title |
---|---|---|
WO2017106964A1 | Methods of treating cancer by inhibition of dna repair proteins using antisense based therapies | |
EP2683825A1 | Methods of treating cancer by inhibition of dna repair proteins | |
US2008255066A1 | Antisense oligonucleotide strategies for the enhancement of cancer therapies | |
WO2006094406A1 | Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof | |
WO2005093090A1 | Antisense oligonucleotides and uses thereof in improving cancer treatment strategies | |
WO2005070469A1 | Methods of treating mesothelioma using an antisense oligonucleotide to thymidylate synthase | |
AU2003221570A8 | Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies | |
WO03086416A1 | Combinations of antisense oligonucleotides directed against thymidylate synythase mrna and uses thereof | |
EP1017800A1 | Antisense oligonucleotides against thymidylate synthase |